Omni Peptides
GLP3 RT
Couldn't load pickup availability
GLP3 RT (also known as LY3437943) is a synthetic long-acting peptide engineered as a triple agonist of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). This research compound has generated substantial scientific interest for its potential in modulating energy metabolism, appetite regulation, and glucose homeostasis. Preliminary and advanced preclinical studies, along with emerging clinical data, indicate that this may induce significant weight reduction, improve glycemic control, enhance lipid profiles, and promote liver fat reduction through synergistic activation of these incretin and glucagon pathways. Researchers employ this peptide in laboratory and animal models to investigate mechanisms of obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and related metabolic disorders. As a research-grade compound, this is intended exclusively for in vitro and animal studies. Scientists value its balanced potency profile across the three receptors and its utility in advancing understanding of multi-receptor agonism in metabolic regulation.
Research Applications
Storage & Handling
Storage & Handling
Lyophilised vials are stable at −20°C for up to 2 years unopened. Once reconstituted, refrigerate at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles.
Beyond Use Date
Pre-filled formats (cartridge, pen, nasal) carry a beyond-use date of typically 4–8 weeks from receipt. ≥98% purity by HPLC. For in vitro and preclinical research use only — not for human or veterinary use.
— About this compound
GLP3 RT is a synthetic GLP-3 receptor agonist peptide.
GLP3 RT (also known as LY3437943) is a synthetic long-acting peptide engineered as a triple agonist of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). This research compound has generated substantial scientific interest for its potential in modulating energy metabolism, appetite regulation, and glucose homeostasis. Preliminary and advanced preclinical studies, along with emerging clinical data, indicate that this may induce significant weight reduction, improve glycemic control, enhance lipid profiles, and promote liver fat reduction through synergistic activation of these incretin and glucagon pathways. Researchers employ this peptide in laboratory and animal models to investigate mechanisms of obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and related metabolic disorders. As a research-grade compound, this is intended exclusively for in vitro and animal studies. Scientists value its balanced potency profile across the three receptors and its utility in advancing understanding of multi-receptor agonism in metabolic regulation.
Research Applications
Where researchers apply it.
— Verified & Documented
Every vial is backed by a Certificate of Analysis.
Each lot is independently characterised by HPLC and mass spectrometry, with identity, mass and purity documented per batch and available on request.
Additional quality-control testing, including sterility, endotoxin and heavy metals, is conducted periodically across our product range.
Storage & Handling
Storage & Handling
Lyophilised vials are stable at −20°C for up to 2 years unopened. Once reconstituted, refrigerate at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles.
Beyond Use Date
Pre-filled formats (cartridge, pen, nasal) carry a beyond-use date of typically 4–8 weeks from receipt. ≥98% purity by HPLC. For in vitro and preclinical research use only — not for human or veterinary use.